Cytogel Pharma vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cytogel Pharma is a clinical-stage biotech developing CYT-1010, a first-in-class endomorphin-based analgesic for non-addictive pain relief; targets the opioid epidemic with a novel peptide mechanism that provides pain control without addiction risk.
About
Cytogel Pharma is a clinical-stage biopharmaceutical company developing novel, non-addictive pain management therapies as alternatives to traditional opioids. Its lead drug candidate, CYT-1010, is a first-in-class endomorphin-based analgesic — a synthetic peptide that activates opioid receptors in the brain and spinal cord to produce effective analgesia while minimizing or eliminating the euphoric and addictive properties of conventional opioids like oxycodone and morphine.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.